



**Purdue Pharma L.P.**

One Stamford Forum  
Stamford, CT 06901-3431  
[www.purduepharma.com](http://www.purduepharma.com)

August 24, 2015

The Honorable Joe Manchin  
United States Senator  
306 Hart Senate Office Building  
Washington, D.C. 20510

Dear Senator Manchin,

I am writing to address your concerns regarding the pediatric safety and dosing information for OxyContin recently approved by the Food and Drug Administration.


We would like to assure you that Purdue will not promote to pediatricians or other physicians the new pediatric safety and dosing information for OxyContin. While we believe that healthcare professionals must have the necessary safety information when making prescribing decisions, and we are required by law to disclose the product's labeling information when asked, we are also committed to combatting the overuse, misuse, and abuse of prescription opioids. We conduct no direct-to-consumer advertising for OxyContin.

As you know, physicians were able to prescribe opioids to pediatric patients prior to the FDA's decision, yet they may now do so with federally approved safety and dosing information. Also, these new guidelines refer only to patients already being prescribed an opioid.

This company accepted responsibility for its past actions, and since that time Purdue has led our industry in the development of technologies and programs intended to combat the abuse and misuse of prescription drugs. In 2010 we reformulated OxyContin with abuse-deterrent properties, and today we manufacture three of the four opioids with abuse-deterrent properties recognized by FDA. In addition, we have spent more than a decade working alongside policymakers, law enforcement, and public health experts to increase awareness about the risks of prescription opioid misuse and abuse. We are proud of this record and strive each day to build upon it.

We applaud your leadership on this issue and welcome the opportunity to provide additional information about the recent changes to our product labeling, as well as any aspects of our efforts to combat prescription drug abuse.

Sincerely,

  
Gail Cawkwell, MD, PhD  
Chief Medical Officer

*Dedicated to Physician and Patient*